MX2021008022A - Proteínas heterodiméricas para modular células t gamma delta. - Google Patents
Proteínas heterodiméricas para modular células t gamma delta.Info
- Publication number
- MX2021008022A MX2021008022A MX2021008022A MX2021008022A MX2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- heterodimeric proteins
- gamma delta
- modulating gamma
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789344P | 2019-01-07 | 2019-01-07 | |
| US201962876346P | 2019-07-19 | 2019-07-19 | |
| US201962941176P | 2019-11-27 | 2019-11-27 | |
| PCT/US2020/012589 WO2020146393A1 (en) | 2019-01-07 | 2020-01-07 | Heterodimeric proteins for modulating gamma delta t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008022A true MX2021008022A (es) | 2021-08-05 |
Family
ID=71521410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008022A MX2021008022A (es) | 2019-01-07 | 2020-01-07 | Proteínas heterodiméricas para modular células t gamma delta. |
Country Status (13)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566650A (zh) | 2018-06-21 | 2021-03-26 | 沙塔克实验室有限公司 | 异二聚体蛋白及其用途 |
| BR112021013193A2 (pt) * | 2019-01-07 | 2021-09-28 | Shattuck Labs, Inc. | Proteínas heterodiméricas para modulação de células t gama delta |
| WO2022093310A1 (en) * | 2020-10-26 | 2022-05-05 | Shattuck Labs, Inc. | Homodimeric and heterodimeric proteins comprising butyrophilin |
| EP4247409A4 (en) * | 2020-11-19 | 2024-11-13 | Shattuck Labs, Inc. | Methods of identifying gamma delta t cell-modulating agents |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| US20240082306A1 (en) * | 2021-02-03 | 2024-03-14 | Bioheng Therapeutics Limited | Novel chimeric antigen receptor and use thereof |
| JP2024511992A (ja) * | 2021-03-16 | 2024-03-18 | シャタック ラボ,インコーポレイテッド | ガンマデルタt細胞刺激 |
| WO2023102617A1 (en) * | 2021-12-09 | 2023-06-15 | The University Of Melbourne | Modified butyrophilin and butyrophilin complexes |
| WO2023154812A1 (en) * | 2022-02-09 | 2023-08-17 | Shattuck Labs, Inc. | Multispecific heterodimeric proteins |
| WO2024006907A2 (en) * | 2022-06-29 | 2024-01-04 | Shattuck Labs, Inc. | B7h3-targeted gamma delta t cell modulation |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2024191989A1 (en) * | 2023-03-14 | 2024-09-19 | Shattuck Labs, Inc. | Treatment of b cell-mediated diseases by activating cd20-targeted gamma delta t cells |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060264360A1 (en) | 2002-04-12 | 2006-11-23 | Yale University Office Of Cooperstive Research | Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4 |
| US20040053307A1 (en) | 2002-06-17 | 2004-03-18 | Wyeth | Inhibition of T cell activation by butyrophilin 4 and B7-L1 |
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| EP1702622A1 (en) | 2005-03-18 | 2006-09-20 | CONARIS research institute AG | Soluble BTNL2 protein useful to inhibit inflammatory disorders |
| DK1999154T3 (da) * | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2008154516A2 (en) | 2007-06-11 | 2008-12-18 | The Board Of Regents, The Universtity Ot Texas System | Btnl2 fusion protein for t-cell activity modulation |
| GB0717101D0 (en) | 2007-09-03 | 2007-10-10 | Cambridge Entpr Ltd | Tumour marker |
| EP3663318A1 (en) * | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2011127418A1 (en) | 2010-04-09 | 2011-10-13 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| WO2011133886A2 (en) * | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| IN2014CN03887A (cg-RX-API-DMAC7.html) * | 2011-10-27 | 2015-10-16 | Genmab As | |
| US10131709B2 (en) | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
| HUE037186T2 (hu) | 2011-12-28 | 2018-08-28 | Immunoqure Ag | Eljárás humán antitestek izolálására |
| US20150166630A1 (en) | 2012-07-19 | 2015-06-18 | Amgen Inc. | Btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| EP2941438A1 (en) | 2013-01-01 | 2015-11-11 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| GB201300049D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-stimulatory dendritic cells |
| GB201300052D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-suppressive dendritic cells |
| CN110724193B (zh) | 2013-07-03 | 2023-05-05 | 因美诺克股份公司 | 人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用 |
| WO2015001047A1 (en) | 2013-07-03 | 2015-01-08 | Immunoqure Ag | Method of providing anti-human cytokine antibodies for pharmaceutical use |
| CA2917112C (en) | 2013-07-03 | 2022-07-05 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
| US20160376364A1 (en) | 2013-11-29 | 2016-12-29 | Csl Limited | Method of treating cancer |
| EP3087099A4 (en) * | 2013-12-23 | 2017-07-19 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| CN106999584A (zh) | 2014-11-25 | 2017-08-01 | 阿尔伯特爱因斯坦医学院公司 | Btnl9和ermap作为用于免疫疗法的新的免疫系统抑制剂 |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| US20180147257A1 (en) | 2015-05-22 | 2018-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| SG10201913573UA (en) * | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| KR102803158B1 (ko) | 2015-12-02 | 2025-05-08 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| GB201521389D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| CN109071632B (zh) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| EP3436475A1 (en) | 2016-03-29 | 2019-02-06 | STCube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
| WO2018082590A1 (zh) * | 2016-11-02 | 2018-05-11 | 北京蛋白质组研究中心 | 肿瘤免疫治疗靶标及其应用 |
| WO2018201130A1 (en) | 2017-04-28 | 2018-11-01 | The Brigham And Women's Hospital, Inc. | Targeting gamma-delta t cells in obesity and cachexia |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| EP4467146A3 (en) | 2017-09-15 | 2025-05-07 | King's College London | Compositions and methods for enhancing gamma delta t cells in the gut |
| KR102764182B1 (ko) | 2017-09-21 | 2025-02-07 | 임체크 테라퓨틱스 | Btn2에 대해 특이성을 갖는 항체 및 이의 용도 |
| BR112021013193A2 (pt) * | 2019-01-07 | 2021-09-28 | Shattuck Labs, Inc. | Proteínas heterodiméricas para modulação de células t gama delta |
-
2020
- 2020-01-07 BR BR112021013193-0A patent/BR112021013193A2/pt unknown
- 2020-01-07 KR KR1020217023232A patent/KR20210113244A/ko not_active Ceased
- 2020-01-07 WO PCT/US2020/012589 patent/WO2020146393A1/en not_active Ceased
- 2020-01-07 CN CN202080009216.8A patent/CN113329759A/zh active Pending
- 2020-01-07 CA CA3125474A patent/CA3125474A1/en active Pending
- 2020-01-07 MX MX2021008022A patent/MX2021008022A/es unknown
- 2020-01-07 JP JP2021539876A patent/JP2022516964A/ja active Pending
- 2020-01-07 EP EP20738523.8A patent/EP3902557A4/en not_active Withdrawn
- 2020-01-07 PH PH1/2021/551475A patent/PH12021551475A1/en unknown
- 2020-01-07 AU AU2020205965A patent/AU2020205965A1/en not_active Abandoned
- 2020-01-07 SG SG11202106895UA patent/SG11202106895UA/en unknown
- 2020-01-13 US US16/741,146 patent/US11098093B2/en active Active
- 2020-06-03 US US16/891,672 patent/US10988517B2/en active Active
-
2021
- 2021-07-06 IL IL284658A patent/IL284658A/en unknown
- 2021-07-16 US US17/378,110 patent/US20220025000A1/en not_active Abandoned
-
2022
- 2022-06-01 US US17/829,778 patent/US11643447B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL284658A (en) | 2021-08-31 |
| US11098093B2 (en) | 2021-08-24 |
| US20200308238A1 (en) | 2020-10-01 |
| EP3902557A4 (en) | 2023-06-07 |
| US20220025000A1 (en) | 2022-01-27 |
| PH12021551475A1 (en) | 2022-05-02 |
| US11643447B2 (en) | 2023-05-09 |
| WO2020146393A1 (en) | 2020-07-16 |
| AU2020205965A1 (en) | 2021-07-01 |
| SG11202106895UA (en) | 2021-07-29 |
| CN113329759A (zh) | 2021-08-31 |
| EP3902557A1 (en) | 2021-11-03 |
| KR20210113244A (ko) | 2021-09-15 |
| US20230020258A1 (en) | 2023-01-19 |
| BR112021013193A2 (pt) | 2021-09-28 |
| JP2022516964A (ja) | 2022-03-03 |
| US20200216505A1 (en) | 2020-07-09 |
| US10988517B2 (en) | 2021-04-27 |
| CA3125474A1 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002294A (es) | Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1. | |
| PH12021551475A1 (en) | Heterodimeric proteins for modulating gamma delta t cells | |
| MX2021003939A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| ECSP24031979A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| MX2019011570A (es) | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. | |
| MX2022001299A (es) | Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas. | |
| MX370018B (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX2020004568A (es) | Combinación de una terapia celular y un inhibidor de gamma secretasa. | |
| CR20140586A (es) | Celulas para producir iduronato-2-sulfatasa recombinante | |
| EP4545143A3 (en) | Early intervention methods to prevent or ameliorate toxicity | |
| EP4286511A3 (en) | Method to treat cancer with engineered t-cells | |
| BR112015030946A8 (pt) | composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa | |
| CR20190063A (es) | 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2 | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| MX2018003353A (es) | Terapias con celulas cart con una eficacia mejorada. | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| EP4527922A3 (en) | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
| EA201791782A1 (ru) | 4,6-диаминопиридо[3,2-d]пиримидиновые соединения, модулирующие toll-подобные рецепторы | |
| BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| DOP2016000042A (es) | Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos | |
| SV2017005416A (es) | Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados | |
| SV2016005153A (es) | Compuestos y composiciones como inhibidores de la mek | |
| CL2021000446A1 (es) | Métodos para la normalización del metabolismo de aminoácidos |